Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix (NASDAQ: OCUL) has announced inducement awards for a new employee under its 2019 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). The grants, effective March 3, 2025, include:
- A non-statutory stock option to purchase 48,000 shares at market price
- A restricted stock unit (RSU) award for 15,500 shares
The stock option has a 10-year term with a 4-year vesting schedule: 25% vesting on March 3, 2026, and the remainder monthly over three years. The RSU award vests over three years in equal annual installments, starting March 3, 2026. Both awards require continued employment with Ocular through vesting dates.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato premi di incentivazione per un nuovo dipendente ai sensi del suo Piano di Incentivazione Azionaria del 2019, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). I premi, con effetto dal 3 marzo 2025, includono:
- Un'opzione su azioni non statutaria per l'acquisto di 48.000 azioni al prezzo di mercato
- Un premio in unità azionarie vincolate (RSU) per 15.500 azioni
L'opzione su azioni ha un termine di 10 anni con un piano di maturazione di 4 anni: il 25% matura il 3 marzo 2026 e il resto mensilmente per tre anni. Il premio RSU matura in tre anni in rate annuali uguali, a partire dal 3 marzo 2026. Entrambi i premi richiedono la continuazione dell'impiego con Ocular fino alle date di maturazione.
Ocular Therapeutix (NASDAQ: OCUL) ha anunciado premios de inducción para un nuevo empleado bajo su Plan de Incentivo de Acciones de Inducción de 2019, cumpliendo con la Regla de Cotización Nasdaq 5635(c)(4). Las concesiones, efectivas a partir del 3 de marzo de 2025, incluyen:
- Una opción de acciones no estatutaria para comprar 48,000 acciones al precio de mercado
- Un premio de unidades de acciones restringidas (RSU) por 15,500 acciones
La opción de acciones tiene un plazo de 10 años con un calendario de adquisición de 4 años: el 25% se adquiere el 3 de marzo de 2026 y el resto mensualmente durante tres años. El premio RSU se adquiere durante tres años en cuotas anuales iguales, comenzando el 3 de marzo de 2026. Ambos premios requieren la continuación del empleo con Ocular hasta las fechas de adquisición.
Ocular Therapeutix (NASDAQ: OCUL)는 2019년 유도 주식 인센티브 계획에 따라 새로운 직원에 대한 유도 보상을 발표했으며, 이는 나스닥 상장 규칙 5635(c)(4)를 준수합니다. 이 보상은 2025년 3월 3일부터 유효하며, 포함 내용은 다음과 같습니다:
- 시장 가격으로 48,000주를 구매할 수 있는 비법정 주식 옵션
- 15,500주에 대한 제한 주식 단위(RSU) 보상
주식 옵션의 10년 기간은 4년의 분할 일정에 따라 진행됩니다: 2026년 3월 3일에 25%가 분할되고, 나머지는 3년 동안 매달 분할됩니다. RSU 보상은 2026년 3월 3일부터 시작하여 3년 동안 매년 동일한 비율로 분할됩니다. 두 보상 모두 분할 날짜까지 Ocular에서 계속 근무해야 합니다.
Ocular Therapeutix (NASDAQ: OCUL) a annoncé des récompenses d'incitation pour un nouvel employé dans le cadre de son Plan d'Incentive d'Actions d'Induction de 2019, conformément à la Règle de Cotation Nasdaq 5635(c)(4). Les attributions, effectives à partir du 3 mars 2025, comprennent :
- Une option d'achat d'actions non statutaire pour acheter 48 000 actions au prix du marché
- Une attribution d'unités d'actions restreintes (RSU) pour 15 500 actions
L'option d'achat d'actions a une durée de 10 ans avec un calendrier d'acquisition de 4 ans : 25 % sont acquis le 3 mars 2026, et le reste mensuellement sur trois ans. L'attribution RSU s'acquiert sur trois ans en versements annuels égaux, à partir du 3 mars 2026. Les deux attributions nécessitent une poursuite de l'emploi avec Ocular jusqu'aux dates d'acquisition.
Ocular Therapeutix (NASDAQ: OCUL) hat Anreizvergütungen für einen neuen Mitarbeiter im Rahmen seines Anreizaktienplans von 2019 angekündigt, was den Nasdaq-Listing-Regeln 5635(c)(4) entspricht. Die Gewährungen, die ab dem 3. März 2025 wirksam sind, umfassen:
- Eine nicht-statutäre Aktienoption zum Kauf von 48.000 Aktien zum Marktpreis
- Eine Restricted Stock Unit (RSU) Auszeichnung für 15.500 Aktien
Die Aktienoption hat eine Laufzeit von 10 Jahren mit einem 4-jährigen Vesting-Zeitplan: 25% vesten am 3. März 2026, der Rest monatlich über drei Jahre. Die RSU-Auszeichnung vestet über drei Jahre in gleichen jährlichen Raten, beginnend am 3. März 2026. Beide Auszeichnungen erfordern eine fortgesetzte Beschäftigung bei Ocular bis zu den Vesting-Daten.
- None.
- None.
BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee. The awards were made as inducements material to the individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards were granted effective as of March 3, 2025 and consist of (i) a non-statutory stock option to purchase up to 48,000 shares of Ocular’s common stock at a per share exercise price equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant, and (ii) a restricted stock unit award representing the right to receive 15,500 shares of Ocular’s common stock. The stock option has a ten-year term and is scheduled to vest over four years, with
The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral hydrogel or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
What type of inducement awards did Ocular Therapeutix (OCUL) grant in March 2025?
What is the vesting schedule for OCUL's March 2025 stock option grant?
How long is the vesting period for OCUL's March 2025 RSU award?
Under which plan were OCUL's March 2025 inducement awards granted?
